People: Allergan Inc (AGN)

AGN on New York Consolidated

133.92USD
17 Apr 2014
Price Change (% chg)

$2.46 (+1.87%)
Prev Close
$131.46
Open
$130.38
Day's High
$134.41
Day's Low
$129.20
Volume
5,091,091
Avg. Vol
2,940,927
52-wk High
$134.41
52-wk Low
$81.33

Search Stocks

Whitcup, Scott 

Brief Biography

Dr. Scott M. Whitcup, M.D., is Executive Vice President - Research & Development, Chief Scientific Officer of Allergan Inc., since April 2009. Prior to that, Dr. Whitcup was Executive Vice President, Research and Development since July 2004. Dr. Whitcup joined Allergan in January 2000 as Vice President, Development, Ophthalmology. In January 2004, Dr. Whitcup became Allergan's Senior Vice President, Development, Ophthalmology. From 1993 until 2000, Dr. Whitcup served as the Clinical Director of the National Eye Institute at the National Institutes of Health. As Clinical Director, Dr. Whitcup's leadership was vital in building the clinical research program and promoting new ophthalmic therapeutic discoveries. Dr. Whitcup is a faculty member at the Jules Stein Eye Institute/David Geffen School of Medicine at the University of California, Los Angeles. Dr. Whitcup serves on the board of directors of Avanir Pharmaceuticals, Inc., a publicly-traded pharmaceutical company, and Questcor Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company.

Basic Compensation

Total Annual Compensation, USD Long-Term Incentive Plans, USD All Other, USD Fiscal Year Total, USD
1,072,600 -- 2,449,670 3,570,090

Options Compensation

  Quantity Market Value
Exercisable 79,554 2,748,700.00
Unexercisable 79,554 2,832,600.00
Exercised 20,800 1,303,010.00
Name Fiscal Year Total

David Pyott

21,164,200

Douglas Ingram

7,261,320

Jeffrey Edwards

3,156,900

Scott Whitcup

3,570,090

Arnold Pinkston

--

Scott Sherman

--
As Of 30 Dec 2012
Search Stocks